PATHOLOGY & ONCOLOGY RESEARCHVol. 10 No. 4, 2004

 Article

Increased Predisposition to Cancer in Brothers and Offspring of Testicular Tumor Patients

Sarolta GUNDY1, Mária BABOSA3, Márta BAKI2, István BODROGI2

1Department of Onco-Cytogenetics, National Institute of Oncology, Budapest, Hungary
2Department of Chemotherapy, National Institute of Oncology, Budapest, Hungary
3Second Clinic of Paediatrics, Semmelweis University, Budapest, Hungary

 

Cancer susceptibility was examined in first-degree relatives of 293 testicular tumor patients (TTPs) and 586 age-matched healthy males. Significantly increased risk was found in the families of TTPs (OR: 1.4; CI: 1.08-1.79), however, except for testicular cancer of 7 brothers (OR: 11.7; CI: 1.42-256.5), and 6 various childhood tumors (bilateral Wilms' tumor, neuroblastoma, medulloblastoma, ALL, histiocytosis-X, testicular tumor) of 200 offspring (OR: 12.9; CI: 1.54-286.2), no association with other malignancies was observed. No differences were seen between the fertility of patients and controls when occupational or socio-economic status of the families was taken into account. However, the majority of the controls (85%) fathered the first child between 20-30 years of age, while only 61% of TTPs had the first child in the same age group. TTPs fathered more girls than boys (P=0.009), and the lower male - higher female ratio of index children was also identical, irrespective of the conception taking place before or after the father’s treatment. Occupations did not, but smoking might have influenced cancer susceptibility of the patients. Aggregation of fraternal testicular tumors, and both dramatically increased cancer risk and altered sex ratio of the offspring indicate a remarkable role of hereditary factors in tumorigenesis and later consequences of a certain portion of testicular malignancies, which must be refined by molecular studies. Pathology & Oncology Research, Vol 10, Nr 4, 197-203, 2004

Key words: testicular cancer; familial cancer risk; childhood tumors


Received: Oct 13, 2004; accepted: Nov 20, 2004
Correspondence: Sarolta GUNDY, Department of Onco-Cytogenetics, National Institute of Oncology, Ráth Gy. u. 7-9. Budapest H-1122, Hungary; Tel: 36/1/224-8779, Fax: 36/1/224-8776; E-mail: gundy@oncol.hu

Click here to get the full-text version in PDF!
ad